Wall Street Analyst Reiterated Exelixis Inc. [EXEL]. What else is Wall St. saying



Exelixis Inc. [NASDAQ: EXEL] gained 2.47% or 0.51 points to close at $21.14 with a heavy trading volume of 2305767 shares. The company report on September 20, 2021 that Exelixis Announces Final Results from Phase 3 COSMIC-311 Pivotal Trial of CABOMETYX® in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ESMO 2021.

– At a median follow-up of 10.1 months, median progression-free survival was 11.0 months for CABOMETYX compared with 1.9 months for placebo –.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


– Results served as a basis for the recent U.S. FDA approval of CABOMETYX for adult and pediatric patients 12 and older with locally advanced or metastatic DTC that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible –.

It opened the trading session at $20.78, the shares rose to $21.43 and dropped to $20.67, the range by which the price of stock traded the whole day. The daily chart for EXEL points out that the company has recorded -8.56% loss over the past six months. However, it is still -30.57% lower than its most recent low trading price.

If we look at the average trading volume of 2.13M shares, EXEL reached to a volume of 2305767 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Exelixis Inc. [EXEL]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for EXEL shares is $31.77 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on EXEL stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

H.C. Wainwright have made an estimate for Exelixis Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 06, 2021. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on June 15, 2021, representing the official price target for Exelixis Inc. stock. Previously, the target price had yet another raise to $23, while Goldman analysts kept a Sell rating on EXEL stock.

The Average True Range (ATR) for Exelixis Inc. is set at 0.57, with the Price to Sales ratio for EXEL stock in the period of the last 12 months amounting to 5.80. The Price to Book ratio for the last quarter was 3.25, with the Price to Cash per share for the same quarter was set at 4.24. Price to Free Cash Flow for EXEL in the course of the last twelve months was 30.76 with Quick ratio for the last quarter at 6.10.

Trading performance analysis for EXEL stock

Exelixis Inc. [EXEL] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 3.12. With this latest performance, EXEL shares gained by 10.28% in over the last four-week period, additionally sinking by -8.56% over the last 6 months – not to mention a drop of -13.54% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EXEL stock in for the last two-week period is set at 64.88, with the RSI for the last a single of trading hit 68.08, and the three-weeks RSI is set at 61.78 for Exelixis Inc. [EXEL]. The present Moving Average for the last 50 days of trading for this stock 18.83, while it was recorded at 20.68 for the last single week of trading, and 21.39 for the last 200 days.

Exelixis Inc. [EXEL]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and Exelixis Inc. [EXEL] shares currently have an operating margin of +11.14 and a Gross Margin at +96.33. Exelixis Inc.’s Net Margin is presently recorded at +11.32.

Return on Total Capital for EXEL is now 6.00, given the latest momentum, and Return on Invested Capital for the company is 6.10. Return on Equity for this stock inclined to 6.27, with Return on Assets sitting at 5.53. When it comes to the capital structure of this company, Exelixis Inc. [EXEL] has a Total Debt to Total Equity ratio set at 2.77. Additionally, EXEL Total Debt to Total Capital is recorded at 2.70, with Total Debt to Total Assets ending up at 2.43. Long-Term Debt to Equity for the company is recorded at 2.61, with the Long-Term Debt to Total Capital now at 2.54.

Reflecting on the efficiency of the workforce at the company, Exelixis Inc. [EXEL] managed to generate an average of $144,607 per employee. Receivables Turnover for the company is 6.92 with a Total Asset Turnover recorded at a value of 0.49.Exelixis Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.10 and a Current Ratio set at 6.20.

Exelixis Inc. [EXEL]: An earnings per share (EPS) analysis

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for EXEL. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Exelixis Inc. go to 46.00%.

An analysis of insider ownership at Exelixis Inc. [EXEL]

There are presently around $5,663 million, or 87.00% of EXEL stock, in the hands of institutional investors. The top three institutional holders of EXEL stocks are: BLACKROCK INC. with ownership of 31,294,943, which is approximately -2.539% of the company’s market cap and around 1.50% of the total institutional ownership; VANGUARD GROUP INC, holding 29,944,880 shares of the stock with an approximate value of $633.03 million in EXEL stocks shares; and FMR LLC, currently with $424.95 million in EXEL stock with ownership of nearly 32.617% of the company’s market capitalization.

>> 7 Top Picks for the Post-Pandemic Economy <<

Positions in Exelixis Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 157 institutional holders increased their position in Exelixis Inc. [NASDAQ:EXEL] by around 19,868,574 shares. Additionally, 172 investors decreased positions by around 13,749,714 shares, while 59 investors held positions by with 234,278,678 shares. The mentioned changes placed institutional holdings at 267,896,966 shares, according to the latest SEC report filing. EXEL stock had 39 new institutional investments in for a total of 1,682,968 shares, while 46 institutional investors sold positions of 2,028,226 shares during the same period.



Download Free eBook For


100% free. stop anytime no spam



Download Free eBook For


100% free. stop anytime no spam